India’s pharmaceutical sector is projected to post healthy revenue growth of 7-9 per cent in FY26, aided by robust demand in the domestic and European markets, even as momentum in the United States is expected to cool, according to rating agency ICRA.
The domestic market is expected to expand by 8-10 per cent and Europe by 10-12 per cent, while US revenues could moderate to 3-5 per cent in FY26 compared with nearly 10 per cent growth in FY25, the agency said in its latest outlook, PTI reported.
“Operating profit margins of the sample entities are expected to remain resilient at 24-25 per cent in FY26, broadly in line with 24.6 per cent in FY25, aided by favourable raw material prices, improved operating leverage and a rising share of speciality products,” ICRA noted.
Research and development spending is projected at 6-7 per cent of revenues, with companies stepping up investments in complex molecules and speciality products over generics.
ICRA also estimates total capital expenditure for its sample set to reach Rs 42,000-45,000 crore in FY26, including Rs 25,000 crore in inorganic investments.
The TOI Business Desk is a vigilant and dedicated team of journal...
Read MoreThe TOI Business Desk is a vigilant and dedicated team of journalists committed to delivering the latest and most relevant business news from around the world to readers of The Times of India. The primary focus of the TOI Business Desk is to keep a watchful eye on the global business landscape, covering a wide spectrum of industries, markets, economic trends, in-depth analysis, exclusive reports and breaking stories that impact businesses and economies. With a mission to provide valuable insights and updates, the desk ensures that TOI readers are well-informed about the ever-changing and dynamic world of commerce and can navigate the complexities of the business world.
Read Less
Start a Conversation
Post comment